Crinetics Pharmaceuticals, Inc. (CRNX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Diego, CA, United States. The current CEO is R. Scott Struthers.
CRNX has IPO date of 2018-07-18, 437 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $4.16B.
Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead candidate, Paltusotine, is an oral somatostatin receptor type 2 agonist that has completed Phase III trials for acromegaly and Phase II trials for carcinoid syndrome and nonfunctional neuroendocrine tumors. Crinetics is also advancing two additional pipeline programs: CRN04777, a somatostatin type 5 receptor agonist in Phase I development for congenital hyperinsulinism, and CRN04894, an adrenocorticotrophic hormone antagonist in Phase I trials for Cushing's disease and congenital adrenal hyperplasia. Founded in 2008 and headquartered in San Diego, California, the company focuses on addressing significant unmet medical needs in endocrinology.
